This article is more than 5 years old. Information may no longer be current.
Aton Pharma begins promotional campaign for preservative-free glaucoma medication
Click Here to Manage Email Alerts
LAWRENCEVILLE, N.J. — Aton Pharma announced the launch of education, marketing and distribution programs for Timoptic in Ocudose, the company announced in a press release.
Timoptic (timolol maleate), a nonselective beta-blocker indicated for elevated IOP associated with ocular hypertension or open-angle glaucoma, is the only preservative-free glaucoma medication available in the United States. Aton acquired U.S. marketing rights to the drug from Merck & Co. in February.
"A preservative-free beta-blocker is a consideration for many glaucoma patients who must use medication frequently and for long periods of time," William B. Trattler, MD, director of cornea at the Center for Excellence in Eye Care in Miami, said in the release. "This is a particular concern for those who already have dry eye or are at increased risk for ocular surface disease, such as the elderly, those on oral medications associated with dry eye and patients with existing lid margin disease. The use of a preservative-free medication such as Timoptic in Ocudose can help preserve the health of the ocular surface in glaucoma patients."
In a recent national survey of ophthalmologists sponsored by Aton, 97% of respondents said preservative-free glaucoma medications could enhance ocular comfort among glaucoma patients; 86% of respondents said preservative-free glaucoma medication could enhance patient quality of life.
Additionally, 89% of responding physicians said there were not enough preservative-free glaucoma medications on the market, and 47% said they were not aware a preservative-free beta-blocker was available.
Aton sales representatives will reintroduce the agent to eye care professionals. The company is also launching a patient education Web site at www.ocudose.com.